2 July 2009
This paper has gathered that as of July 1, 2009 a clinical trial is being launched in three African countries of a drug that could eliminate onchocerciasis, or river blindness, one of the leading infectious causes of blindness across Africa, the World Health Organization has indicated.
According to reports, the drug, known as moxidectin, is being investigated for its potential to kill or sterilize the adult worms of Onchocerca volvulus, which cause onchocerciasis. Medical authorities around the world have given a rather grim picture of the devastating potential of the disease which was spotted in Liberia years back and is blamed on several blind cases in the rural parts of the country.
Yesterday a teleconference was held in three African countries including Liberia during which those behind efforts to fight the spread of the disease provided detailed information as to its danger and what is being to eliminate it. The teleconference was about given more information regarding the new drugs which is being tested to eliminate the illness.
"This is a devastating illness that has plagued 30 African countries for centuries, in particular the populations in the most remote areas 'beyond the end of the road'," says Dr Uche Amazigo, Director of the African Programme for Onchocerciasis Control (APOC). "Over 100 million people are at risk of infection with onchocerciasis in Africa and a few small areas in the Americas and Yemen." But when asked as to how many people here in Liberia are affected by the illness, authorities could not give any statistics on grounds "it was not available to them.
Authorities say the illness or Onchocerciasis is also called river blindness because the black fly which transmits it breeds in fast flowing rivers, and blindness is the most incapacitating symptom of the disease which also causes debilitating skin disease.
The development of moxidectin for onchocerciasis is being conducted through a collaboration of the Special Programme for Research and Training in Tropical Diseases, which is executed by the World Health Organization (WHO/TDR), and Wyeth Pharmaceuticals.
The work ranges from the development of a formulation for human use and initial studies in healthy volunteers, to clinical studies and community studies in Africa. WHO/TDR, working in partnership with African investigators and institutions, is building the capacity and managing the conduct of the clinical trials conducted in Africa.
"If the development is successful and results in a positive scientific opinion from the European Medicines Evaluation Agency, Wyeth, with the assistance of WHO, will request approval by national regulatory authorities in the countries where onchocerciasis is endemic," authorities say.
Dr Henrietta Ukwu, Vice President, Wyeth Pharmaceuticals, one of the specialists who addressed the teleconference yesterday says, "Wyeth is committed to improving access to innovative drugs and biologics around the globe including in the developing world. The moxidectin data have been promising so far, and as the programme moves into larger phase III studies, we are hopeful that moxidectin will constitute a significant advance against this devastating disease."
In conducting this trial, it is learned that TDR will be working with African investigators and institutions. Fifteen hundred people at 4 sites in Ghana, Liberia and the Democratic Republic of Congo will be enrolled in the study. More than that, it is gathered also that preparation has been ongoing since 2007, and included building a clinical research centre in Lofa County, Liberia, and in Nord-Kivu in the Democratic Republic of Congo (DRC).
Dr. Robert Ridley, TDR's director, says, "We work with national authorities and country partners to build research capacity and infrastructure. The training we provide to researchers and health care professionals and the experience they gather during the TDR sponsored studies enables them to conduct other clinical research later on, strengthening the health research systems in those countries."
Authorities have indicated that the trial will take place over the next two and a half years. Currently, the disease is controlled by ivermectin, which has been donated for more than 20 years by the pharmaceutical company Merck & Co., Inc., for use in onchocerciasis endemic countries.
Treatment with ivermectin has enabled significant progress in the control of onchocerciasis, and currently reaches more than 60 million people in Africa annually. However, ivermectin kills the O. volvulus larvae but not the adult worms, so annual treatments for an extended period of time (at least 11-14 years) are required to ensure disease control.
"If moxidectin kills not only the larvae but also sterilizes or kills the adult worms, it has the potential to interrupt the disease transmission cycle within around 6 annual rounds of treatment. The drug could be distributed through the community-directed mechanisms set up in collaboration among APOC, African control programmes, and NGOs for the distribution of ivermectin," MHO/TDR has indicated.
Be the first to Write a Comment!
Copyright © 2009 The Analyst. All rights reserved. Distributed by AllAfrica Global Media (allAfrica.com). To contact the copyright holder directly for corrections — or for permission to republish or make other authorized use of this material, click here.
AllAfrica aggregates and indexes content from over 125 African news organizations, plus more than 200 other sources, who are responsible for their own reporting and views. Articles and commentaries that identify allAfrica.com as the publisher are produced or commissioned by AllAfrica.
